However, prolonged stable disease was achieved for chondrosarcoma patients by combining mTOR inhibitors with liposomal doxorubicin or EGFR, IGF1R, VEGF inhibitors (Katz et al., 2016; Liu et al., 2016; Trucco et al., 2018; Vlahovic et al., 2018). This evidence concerns the gene EGFR and chondrosarcoma.